Product Information

Human Platelet Lysate (hPL) is a solution obtained by lysing human platelets. It contains a rich mix of growth factors, cytokines and other bioactive molecules that stimulate cell growth, regeneration and tissue repair. This makes it therefore ideally suited as a xeno-free supplement for (stem) cell culture in cell therapy production, among others. The development of hPL Gold and Platinum allows our provider to make the best use of all blood donations, as well as making an additional contribution to improved patient care.

hPL is made from exclusively human material, thus no animal products are involved. This not only increases compatibility with human cell culture but eliminates the risk of zoonotic infections as with FBS. When ultimately used for clinical purposes, there is no risk of patient immunization against animal proteins and is an additional argument to the regulator for approving your cultured cells.

Choosing hPL over FBS is also recommended for research groups. Not only is hPL often more efficient than FBS, it is, above all, an important choice for the long term of your project. When translating to a clinical setting by you or third parties, the use of FBS during research is a distinct disadvantage as it necessitates a switchover from FBS to hPL. As a result, your costly research must be re-lined with hPL. Using hPL Gold or Platinum from the starting line anticipates problems later in your path.

The preparation of hPL from donor to final product lies entirely with our preferred partnering blood establishment, thus we have excellent control over correct storage and handling of all source, intermediate and final products. During our development, production in a closed system was crucial, so the hPL never comes into contact with ambient air, whereas FBS or hPL from competitors often ends up in open systems both during collection at the slaughterhouse and during production.

Since the source product of hPL is standardized to meet strict requirements for transfusion, the batch-to-batch variation of hPL is a lot lower than for FBS. In addition, donor material from multiple donors is pooled, further reducing batch-to-batch variation.

Our partnering blood establishment has developed an innovative method to produce lysates from human blood platelets. The technique ensures that expired platelets are not lost and animal suffering is avoided.

Each year, thousands of platelet concentrates are discarded. As these can only be stored for five days, up to 10 per cent are destroyed. Our partnering blood establishment has now developed a biotech product that can make use of these “expired” platelets.  Thanks to the new technique, the platelets can be used to develop growth serum, an important starting product for the development of vaccines or in cell and genetic engineering.